Preeti Purwaha

Dr. Preeti Purwaha


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2018 in Metabolites
Verified
Journal Article
Open access
PDF file
PPPreeti Purwaha
Preeti Purwaha
FGFranklin Gu
Franklin Gu
DPDanthasinghe Waduge Badrajee Piyarathna
Danthasinghe Waduge Badrajee Piyarathna
TRTheckelnaycke Rajendiran
Theckelnaycke Rajendiran
ARAnindita Ravindran
Anindita Ravindran
ASArun Sreekumar
Arun Sreekumar
The reprogramming of lipid metabolism is a hallmark of many cancers that has been shown to promote breast cancer progression. While several lipid signatures associated with breast cancer aggressiveness have been identified, a comprehensive lipidomic analysis specifically targeting the triple-negative subtype of breast cancer (TNBC) may be required to identify novel biomarkers and therapeutic targets for this most aggressive subtype of breast cancer that still lacks effective therapies. In this current study, our global LC-MS-based lipidomics platform was able to measure 684 named lipids across 15 lipid classes in 70 TNBC tumors. Multivariate survival analysis found that higher levels of sphingomyelins were significantly associated with better disease-free survival in TNBC patients. Furthermore, analysis of publicly available gene expression datasets identified that decreased production of ceramides and increased accumulation of sphingoid base intermediates by metabolic enzymes were associated with better survival outcomes in TNBC patients. Our LC-MS lipidomics profiling of TNBC tumors has, for the first time, identified sphingomyelins as a potential prognostic marker and implicated enzymes involved in sphingolipid metabolism as candidate therapeutic targets that warrant further investigation.